- Home
- EQS vs APLM Comparison
EQS vs APLM Comparison
Compare EQS & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- APLM
- Stock Information
- Founded
- EQS 1991
- APLM 2016
- Country
- EQS United States
- APLM United States
- Employees
- EQS N/A
- APLM N/A
- Industry
- EQS Finance Companies
- APLM Blank Checks
- Sector
- EQS Finance
- APLM Finance
- Exchange
- EQS Nasdaq
- APLM Nasdaq
- Market Cap
- EQS 14.9M
- APLM 12.3M
- IPO Year
- EQS N/A
- APLM N/A
- Fundamental
- Price
- EQS $1.23
- APLM $9.51
- Analyst Decision
- EQS
- APLM Strong Buy
- Analyst Count
- EQS 0
- APLM 2
- Target Price
- EQS N/A
- APLM $425.00
- AVG Volume (30 Days)
- EQS 15.3K
- APLM 23.2K
- Earning Date
- EQS 01-01-0001
- APLM 02-15-2025
- Dividend Yield
- EQS N/A
- APLM N/A
- EPS Growth
- EQS N/A
- APLM N/A
- EPS
- EQS N/A
- APLM N/A
- Revenue
- EQS $1,137,000.00
- APLM $2,101,000.00
- Revenue This Year
- EQS N/A
- APLM N/A
- Revenue Next Year
- EQS N/A
- APLM N/A
- P/E Ratio
- EQS N/A
- APLM N/A
- Revenue Growth
- EQS 1795.00
- APLM 70.54
- 52 Week Low
- EQS $1.01
- APLM $6.50
- 52 Week High
- EQS $1.95
- APLM $85.00
- Technical
- Relative Strength Index (RSI)
- EQS 56.18
- APLM 46.26
- Support Level
- EQS $1.01
- APLM $8.94
- Resistance Level
- EQS $1.37
- APLM $10.02
- Average True Range (ATR)
- EQS 0.09
- APLM 0.86
- MACD
- EQS 0.02
- APLM -0.08
- Stochastic Oscillator
- EQS 61.11
- APLM 18.57
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invest primarily in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts and recapitalizations of existing businesses or special situations and achieve capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.